Association of miR-375 downregulation with clinicopathological features of 60 ESCC patients
| Clinicopathological features | Total case (%) | miR-375 expression | p Value | |
| Negative (%) | Positive (%) | |||
| Sex | ||||
| Male | 43 (71.67) | 76.74 | 23.26 | 0.461 |
| Female | 17 (28.33) | 82.35 | 17.65 | |
| Age, years | ||||
| ≤66 | 23 (38.33) | 78.26 | 21.74 | 0.617 |
| >66 | 37 (61.67) | 78.38 | 21.62 | |
| Clinical Stage | ||||
| Early stage (I–II) | 22 (36.67) | 56.45 | 43.55 | 0.003* |
| Advanced stage (III–IV) | 38 (63.33) | 92.1 | 7.9 | |
| Distant metastasis | ||||
| M0 | 46 (76.67) | 86.79 | 13.21 | <0.0001 |
| M1 | 14 (23.33) | 14.29 | 85.71 | |
| Tumour size | ||||
| ≤5 cm | 21 (35) | 89.66 | 10.34 | 0.187 |
| >5 cm | 39 (65) | 68.75 | 31.25 | |
↵* Significant difference.
ESCC, oesophageal squamous cell carcinoma.